Linezolid
Drug
Shionogi Inc
Total Payments
$88,317
Transactions
46
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $21,930 | 12 | 0 |
| 2018 | $52,418 | 30 | 0 |
| 2017 | $13,969 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $88,317 | 46 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Clinical Study of S-649266 for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens APEKS-NP | Shionogi Inc | $88,317 | 0 |
Top Doctors Receiving Payments for Linezolid
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Deland, FL | $88,317 | 46 |
Ad
Manufacturing Companies
- Shionogi Inc $88,317
Product Information
- Type Drug
- Total Payments $88,317
- Total Doctors 0
- Transactions 46
About Linezolid
Linezolid is a drug associated with $88,317 in payments to 0 healthcare providers, recorded across 46 transactions in the CMS Open Payments database. The primary manufacturer is Shionogi Inc.
Payment data is available from 2017 to 2019. In 2019, $21,930 was paid across 12 transactions to 0 doctors.
The most common payment nature for Linezolid is "Unspecified" ($88,317, 100.0% of total).
Linezolid is associated with 1 research study, including "Clinical Study of S-649266 for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens APEKS-NP" ($88,317).